Status:
COMPLETED
Pregabalin In Partial Seizures Extension Study
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Seizures
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
To evaluate long-term efficacy and safety of pregabalin (150 to 600mg/day) as adjunctive treatment in patients with partial seizures.
Eligibility Criteria
Inclusion
- met the inclusion/exclusion criteria for A0081005
- have completed the 21-week study and have shown a significant clinical response and wish to continue treatment
Exclusion
- Having a treatable cause of seizure.
- Having a progressive neurological or systemic disorder
Key Trial Info
Start Date :
April 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2007
Estimated Enrollment :
227 Patients enrolled
Trial Details
Trial ID
NCT00143130
Start Date
April 1 2005
End Date
September 1 2007
Last Update
January 28 2021
Active Locations (47)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Bruges, Belgium, B-8000
2
Pfizer Investigational Site
Brussels, Belgium, 1070
3
Pfizer Investigational Site
Duffel, Belgium, B-2570
4
Pfizer Investigational Site
Ghent, Belgium, 9000